David A. Siegel Aytu Biopharma, Inc Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.15 - $4.0 $120 - $3,200	-800 Reduced 3.19%	24,300 $4,000
Q3 2022 Nov 14, 2022	SELL	$0.19 - $3.8 $399 - $7,980	-2,100 Reduced 7.72%	25,100 $5,000
Q2 2022 Aug 15, 2022	BUY	$0.46 - $1.08 $1,610 - $3,780	3,500 Added 14.77%	27,200 $19,000
Q1 2022 May 16, 2022	BUY	$1.08 - $1.55 $6,771 - $9,718	6,270 Added 35.97%	23,700 $26,000
Q4 2021 Feb 14, 2022	BUY	$1.35 - $2.95 $23,530 - $51,418	17,430 New	17,430 $24,000
Q2 2021 Aug 16, 2021	SELL	$4.73 - $7.56 $69,119 - $110,474	-14,613 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.23 - $9.88 $91,038 - $144,376	14,613 New	14,613 $111,000

Ticker AYTU
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 62,432,700
Market Cap $102M
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT f...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.